Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Lymphoid 10Myeloid 8Plasma cell 4Classical hematology 4Dermatologic 2Sarcoma 1Other neoplasm 1Genitourinary 1CNS 1Breast 1

Conditions

Non-Malignant Neoplasm 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Docetaxel 2thymoglobulin 1ruxolitinib 1fludarabine 1alethine 1Stem Cell Transplantation 1Sirolimus 1Phenytoin 1Methotrexate 1Irinotecan 1Infusions, Intravenous 1Ifosfamide 1High-Intensity Focused Ultrasound Ablation 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Endoscopy 1Cyclosporine 1Cyclophosphamide 1Celecoxib 1Carboplatin 1CPI-0610 1Busulfan 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Antilymphocyte Serum × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡